is compounded semaglutide approved by the fda crackdown on off-brand Ozempic products set to take effect, threatening supply and access for many The FDA has received reports

In an additional, 30-week placebo-controlled, trial of patients with type 2 diabetes mellitus inadequately controlled with metformin comparing the maintenance of sitagliptin 100 mg versus withdrawal of sitagliptin when initiating basal insulin therapy, the event rate and incidence of documented symptomatic hypoglycemia (blood glucose measurement 70 mg/dL) did not differ between the sitagliptin and placebo groups

I'm loving this product and can't wait to get rid of my dad bod

Ireland, NP Tejaswi Kompala, MD Jessica J

The trickier moment comes later, at home

We are not a compounding pharmacy, clinical laboratory, or compounding facility as defined under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act